We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » TEVA SHIPS GENERIC OXYCONTIN AT RISK WHILE ENDO HOLDS BACK
TEVA SHIPS GENERIC OXYCONTIN AT RISK WHILE ENDO HOLDS BACK
April 6, 2004
Despite unresolved patent issues, Teva Pharmaceutical on March 30 launched the first generic version of Purdue Pharma’s lucrative pain drug OxyContin (oxycodone) 80-mg strength extended-release tablets.